Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Mohamad Moussa,1 Athanasios Papatsoris,2 Mohamed Abou Chakra,1 Athanasios Dellis2,3 1Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon; 2 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University...
Saved in:
Main Authors: | Moussa M (Author), Papatsoris A (Author), Abou Chakra M (Author), Dellis A (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2021-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
by: Christina D. Enescu, BS, et al.
Published: (2022) -
First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023) -
Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
by: Kok Hoe Chan MD, et al.
Published: (2024) -
Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024) -
Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial
by: Maojin You, et al.
Published: (2024)